Lineage Cell Therapeutics, Inc. Recorded Big Gain

Lineage Cell Therapeutics, Inc. (LCTX:NYSEMKT) jumped higher at $1.31, a gain of 21.3%. The stock got featured on our News Catalysts scanner on Thu 06 Feb 20 at 08:24 AM in the 'BIOTECH' category. From Wed 15 Jan 20, the stock recorded 57.14% Up Days and 53.33% Green Days

The share price of the company has been moving sideways in recent weeks.

About Lineage Cell Therapeutics, Inc. (LCTX:NYSEMKT)

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. BioTime's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.